Skip to main content

ACET

Stock
Health Care
Biotechnology

Performance overview

ACET Price
Price Chart

Forward-looking statistics

Beta
1.39
Risk
77.03%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Company info

SectorHealth Care
IndustryBiotechnology
Employees137
Market cap$110.9M

Fundamentals

Enterprise value-$83.7M
Revenue$0.0
Revenue per employee—
Profit margin0.00%
Debt to equity10.06

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.29
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$331K
Avg trading volume (10 day)$348K
Put-call ratio—

Macro factor sensitivity

Growth-10.0
Credit+14.6
Liquidity+4.2
Inflation-12.7
Commodities-6.3
Interest Rates-2.1

Valuation

Dividend yield0.00%
PEG Ratio-0.46
Price to sales—
P/E Ratio-0.46
Enterprise Value to Revenue—
Price to book0.31

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day—
Ex. dividend day—

News

Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know

Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (May 9, 2025)
If we do enter a recession next year, we'll see more of a rotation into health care, says RTW's Wong

Dr. Rod Wong, RTW Investments managing partner and CIO, joins the 'Halftime Report' to discuss his thoughts on the biotech sector going into the new year, his investing thesis behind Avidity Biosciences and more.

CNBC Television (November 18, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free